香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 近日，中国光大环境（集团）有限公司（257.HK）（下称“光大环境”或“公司”）公布了2024中期业绩。作为一站式、全方位的环境综合治理服务商，光大环境不仅保持业务稳健增长，更在环境保护和社会责任方面发挥重要作用，引领行业标杆。绿色科创赋能未来 广泛推动绿色合作光大环境积极参与高层行业对话和国际论坛，推动区域环境合作。2024年上半年，公司管理层先后出席了美丽中国百人论坛2024年会、上海合作组织国家绿色发展论坛。在上海合作组织国家绿色发展论坛上，光大环境与各国代表共同探讨绿色发展战略，为全球绿色发展贡献中国方案。论坛期间，光大环境总裁栾祖盛参与了“产业集聚共建繁荣上合”主题环节，并以《发展绿色生产力 共建可持续未来》为题发言，重点分享了开展务实科技交流，构建绿色创新生态圈；推动低碳产能合作，打造绿色产业聚集区；加快标志项目落地，树立绿色上合新标杆三方面的思考。此外，公司作为参建单位受邀还出席了海南博鳌近零碳示范区运行启动会。今年上半年，公司旗下越南顺化垃圾发电项目竣工仪式获越南国家政府总理出席，同时，公司亦受邀出席越南总理与在越中资企业的座谈会，展示了中国企业在“一带一路”倡议下的担当和影响力。公开透明沟通 提升市场形象秉持开放透明的原则，光大环境主动接受各界监督，展现了高度的企业责任感和治理水平。2024年上半年，公司组织了近20次项目考察活动，吸引逾百家境内外投资机构参加。这些考察活动涵盖了公司在垃圾发电、水环境治理、生物质能利用等多个领域的代表性项目，让投资者、分析师和媒体代表深入了解了光大环境的运营模式、技术创新和发展战略。通过面对面交流和实地考察，公司深化了与各利益相关方的沟通，增进了相互理解和信任。这种开放、透明的沟通策略不仅提升了公司的市场形象，也为吸引更多投资者和合作伙伴奠定了坚实基础。截至2024年6月30日，已有23家机构给予光大环境正面评级，公司股价较2023年底升逾50%。倡导环保低碳 携手各界筑绿光大环境积极推动环保宣传，致力于提升公众的环保意识和参与度。在内地，公司围绕“世界水日”、“世界环境日”等重要环保主题日，在全国各地的项目公司组织开展了形式多样、内容丰富的环保活动。在日常亦通过策划并组织主题形式多样的公益活动，深入当地社区，与民众互利共融，吸引了大量市民参与，有效普及了环保知识，培养了公众的环保习惯。截至2024年6月30日，光大环境累计有220个项目向公众开放，线下接待境内外各界参观考察人士约9,500人次，参与和观看线上活动的人数约8万人次。获颁多项荣誉，巩固行业影响力2024年上半年，光大环境凭借卓越的经营业绩和社会贡献，收获多项荣誉。公司连续13年位居中国“年度固废十大影响力企业”榜首，获标普第七次纳入《可持续发展年鉴》；旗下光大水务连续7年入选“中国水业十大影响力企业”榜单；光大绿色环保更是第3次获评《亚洲周刊》全球卓越ESG大奖。这些荣誉和成就进一步巩固了光大环境在环保领域的领军地位，为公司未来的发展注入了强劲动力。面对国家“双碳”目标和对照中国式现代化建设目标要求，作为行业领军企业，光大环境在推动绿色低碳发展、改善生态环境质量、促进经济社会可持续发展等方面发挥了重要作用。公司管理层表示，未来，光大环境将继续秉持“创造更好投资价值，承担更多社会责任”的企业使命，坚持创新驱动，深化国际合作，不断提升环境治理能力和水平，为中国生态文明建设和全球可持续发展贡献更大力量。 Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 渤海银行股份有限公司（「渤海银行」或「公司」；股份代号：9668.HK）宣布公司及其附属公司（「集团」）截至2024年6月30日止六个月（「报告期」）之未经审计综合中期业绩。2024年上半年，国际环境更趋复杂严峻，主要经济体经济增长与货币政策有所分化。中国经济运行延续回升向好态势，高质量发展扎实推进，但仍面临有效需求不足、企业经营压力较大、重点领域风险隐患较多等困难。集团全面落实监管政策要求，坚持稳中求进工作总基调，以进促稳，先立后破，持续推进「十个专项工作」攻坚，扎实落地高质量发展方案各项目标任务，优化业务布局，狠抓科技创新，突出转型驱动，强化风险防控，在转方式、调结构、提质量、增效益上积极进取，推动高质量发展取得新成效。报告期内，集团实现营业收入131.45亿元，净利润36.97亿元，总体保持了平稳发展态势。截至报告期末，资产总额17,479.96亿元，较上年末新增152.62亿元，增幅0.88%。其中，发放贷款和垫款总额（未含应计利息）为9,478.52亿元，较上年末新增152.08亿元，增幅1.63%；负债总额16,294.25亿元，较上年末新增110.94亿元，增幅0.69%。其中，吸收存款总额（未含应计利息）9,346.22亿元，较上年末新增194.60亿元，增幅2.13%；不良贷款余额为171.12亿元，比上年末增加5.54亿元；不良贷款率为1.81%，比上年末上升0.03个百分点。贷款损失准备计提充足，贷款减值准备271.07亿元，比上年末增加11.20亿元。贷款拨备率2.86%，拨备覆盖率158.41%，均符合监管要求。回归服务实体经济本源 扎实推进公司银行业务高质量转型报告期内，公司银行以服务国家战略目标和实体经济为根本宗旨，紧紧围绕做好科技金融、绿色金融、普惠金融、养老金融、数字金融五篇大文章，坚持行业银行、交易银行、轻型银行定位，优化业务结构，提升经营水平，扎实推进公司银行业务高质量转型发展。客户建设方面，报告期内，公司银行坚持以客户为中心，持续完善行业战略客群、基础专项客群、政府机构客群、区域重点客群等四大对公客群服务体系。截至报告期末，公司银行全量客户合计111,472户，比上年末增加6,040户，增长5.73%。负债业务方面，公司银行始终坚持「存款为本」的理念，通过传统及非传统信贷产品组合应用，搭建业务场景，为客户提供综合金融服务，积极拓展低成本存款。同时，推进数字化系统建设，完善产品功能，提升服务水平，优化客户体验，推动存款规模增长和存款结构优化。截至报告期末，公司存款总额5,942.76亿元，比上年末增加281.09亿元，增长4.96%。资产业务方面，公司银行围绕服务实体经济，持续加大对科技金融、制造业、绿色信贷、乡村振兴等重点领域的支持力度。制造业、科创类小微企业、绿色金融、涉农等重点领域贷款增速均大幅高于一般性贷款增速。截至报告期末，公司贷款总额6,366.66亿元，比上年末增加699.26亿元，增长12.34%。科技企业贷款余额438.95亿元，其中专精特新企业贷款余额同比增长23.03%，高技术产业贷款余额同比增长22.08%，知识产权密集型产业贷款余额同比增长12.79%；制造业贷款余额912.79亿元，较上年末增长6.84%；绿色贷款余额377.45亿元，较上年末增长20.75%；涉农贷款余额419.16亿元，较上年末增长15.62%。交易银行业务方面，交易银行持续加强产品化、场景化、线上化建设，围绕供应链金融、票据服务、现金管理解决方案、国际结算与贸易融资，构筑交易银行业务生态，深挖客户需求，为客户提供一站式服务体验。报告期内，交易银行实现非息收入9.60亿元，同比增长5.73%。其中，价差收入1.43亿元，同比增长268.98%。交易银行业务表内外资产规模4,707.4亿元， 同比增长14.17%；累计投放4,347.77亿元，同比增长78.23%。全行线上公司业务客户数13,286户，新一代票据业务活跃客户数2,109户。实现国内信用证及福费廷业务投放1,163.61亿元。海纳池累计投放金额124.19亿元，在池资产规模156.54亿元。投资银行业务方面，集团坚定FPA经营发展转型方向，着力打造流量银行，盘活存量、用好增量、做大流量，以具有比较优势的钩子产品作为业务破局点，将服务经济融资总量作为工作的出发点和落脚点，持续优化业务结构、丰富收入来源、发力渠道拓展、夯实客户基础，强化通过债券承销、交易撮合、资产流转、理财子公司对接等高效利用资本方式实现拓展客户、沉淀存款、提升效益的能力。2024年上半年，投资银行债券主承销业务规模913.56亿元，同比增长105.48%；累计承销各类创新债券（含结构化融资产品）31只，承销金额合计120.17亿元。交易撮合业务稳步发展，报告期内，撮合对接资产规模433.25亿元，同比增长5.78%。资产托管业务方面，报告期内，资产托管业务扎实履行服务实体经济高质量发展职能，坚持专业化、规范化发展，持续优化运营流程，夯实客户基础，探索创新服务模式，推动托管规模快速提升。截至报告期末，资产托管及外包业务规模余额28,058.55亿元；报告期内，实现资产托管及外包业务收入15,417.77万元。根据中国银行业协会2024年第二季度统计数据，集团托管规模排名第20位。普惠金融业务方面，报告期内，集团重点聚焦普惠金融产品谱系打造，着力构建「链系列、数系列、快系列、科系列」四大普惠金融产品谱系，实现线上线下相结合，大幅提升服务效率和客户体验，打造具有渤海特色的普惠服务品牌。截至报告期末，集团普惠贷款余额457.35亿元；普惠贷款客户数87,402户；当年累放贷款执行利率4.4%。着力打造账户银行、财富银行、生态银行 零售银行业务稳步发展报告期内，零售银行着力打造账户银行、财富银行、生态银行，推进「账户+支付+金融产品」的综合服务体系建设，强化生态拓客模式，依托技术支撑和数字驱动，深化客户分层分群经营，以客户视角聚合产品服务，优化产品谱系，改善业务结构，推进零售业务稳步发展。截至报告期末，集团零售存款余额2,103.19亿元，较上年末增加93.17亿元。客户发展方面，集团加快数字化运营能力突破，聚焦多元渠道建设、拓客模式转型和生态场景搭建，完善客户分层分群经营服务策略，优化代发和支付服务工具，促进零售客户增量提质。截至报告期末，集团零售客户总量793.18万户，较年初净增21.93万户。资产业务方面，报告期内，零售资产业务以国家信贷政策为导向，加快推进业务高质量转型发展，坚持以客户为中心，满足客户多样化信贷需求。截至报告期末，个人贷款余额2,247.65亿元。财富管理方面，持续打造「渤银E财」产品货架，提升产品供应能力。报告期内，零售财富资产规模稳步提升，同比增长407.24%，其中代销理财存量规模增速较上年同期提升26.25个百分点，代销信托存量规模同比增长116.14%，发展势头良好。私人银行专业化服务成效日益凸显，截至报告期末，私人银行投资理财类产品的覆盖度较年初提升1.23个百分点。信用卡业务方面，集团聚焦金领贷客群、房贷客群，将信用卡打造成为增强零售优质客群粘性的有效载体。截至报告期末，信用卡累计发卡量126.42万张，贷款规模41.89亿元。提升金融市场业务创新转型发展能力 树立行业口碑报告期内，集团金融市场业务坚决践行转型振兴高质量发展要求，以建设市场领先的金融市场FICC业务中心为目标，牢牢守住风险底线，深耕同业客户基础，强化销售交易能力建设，确保全行流动性安全，金融科技赋能业务发展，坚持金融服务实体经济，各项工作取得显著成果。理财业务方面，集团持续丰富理财产品种类，优化产品功能，为客户提供更好的理财服务。同时积极拓展行外代销渠道，拓宽资产管理服务客群，已与26家机构达成代销合作。报告期内，集团共发行理财产品204只，销售金额合计2,048.85亿元。截至报告期末，集团存续理财产品358只，理财产品余额1,677.01亿元，净值型产品占比91.72%。资金业务方面，密切关注市场走势，加强市场研判，积极开展各类货币市场交易业务，上半年开展人民币债券质押式回购交易约5.57万亿元，同比增长5.96%，获得中国人民银行2024年度公开市场业务一级交易商资质，并获评中国外汇交易中心回购活跃交易商，大幅提高银行间市场影响力。同时，紧抓市场机遇，踊跃参与外汇交易中心各类标准化交易业务，外汇交易各项排名较上年同期均有不同程度的提升，其中人民币外汇掉期交易排名跻身银行间市场45强。债券业务方面，持续加强债券业务模式和产品创新，做大债券投资交易规模，债券市场影响力、货币政策传导能力、双边做市服务能力有效提升。报告期内，各类金融市场债券业务量保持稳步增长，现券交易量2.9万亿元，同比增长70%。同业业务方面，集团持续探索并推进同业客户一体化经营。继续完善同业产品货架，以销售促转型稳步推进，客户综合贡献稳步提升，同业朋友圈更加丰富完备。报告期内，实现属地目标同业客户覆盖率43.4%，多元产品渗透率34.81%。同业授信方面，报告期内，境内外同业机构对集团授信额度充足、品种广泛，满足全行各项业务稳定发展需要。截至报告期末，集团累计获得超过1,300家同业机构授信，授信总额1.6万亿元人民币。聚焦数字金融和智慧金融 持续推进网络金融业务报告期内，集团网络金融业务聚焦数字金融和智慧金融，持续推进线上用户运营和门户渠道建设，通过技术与数据赋能，加速实现综合化服务升级和经营转型发展。手机银行方面，集团重点围绕账户银行、财富银行和生态银行战略定位，逐步从功能建设向客户经营转型并成功升级至6.3版，通过建立事件型营销体系和数字化全域经营促进移动端月活客户数量和财富产品成交量持续提升。门户网站方面，集团于2024年5月完成门户网站系统重构，实现全面升级，为客户提供智能化服务新体验。在生态化经营方面，集团持续深耕教育服务场景，深化场景化服务新模式，打造全方位服务客户的生态体系。展望未来2024年下半年，集团将全面落实监管政策要求，遵金融规律、守金融向善、求金融真实，以改革精神做强主责主业，更加注重统筹联动，更加注重突出重点，更加注重实绩实效，持续集中全力转方式、调结构、提质量、增效益，努力开创高质量发展新局面。 Copyright 2024 亚太商讯 via SeaPRwire.com.

- Dorzagliatin (trade name: HuaTangNing, world's first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “NRDL”) at the end of 2023. Hua Medicine worked with sales promotion partner Bayer Healthcare Company Limited (“Bayer”) and 80 Tier 1 distributors to begin the pharmaceutical market entry in 31 municipalities and provinces in China.- The new NRDL became effective on January 1, 2024. In the first half of 2024, the sales volume of dorzagliatin increased significantly. As of June 30, 2024, sales of HuaTangNing reached 846,000 packs with a sales revenue of RMB102.7 million. The sales revenue increased by 46%, compared with the six months ended June 30, 2023.- Dorzagliatin experienced a fast entry into hospitals, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. By the end of June 30, 2024, dorzagliatin was prescribed in over 2,100 hospitals and over 2,900 pharmacies. Dorzagliatin was sold principally through hospitals (approximately 72% of total sales), with the remainder of sales through pharmacies (20%) and internet drug stores (8%).- Gross profit in the first half of 2024 is RMB47.8 million, representing a gross profit margin of 46.5%. Bank balances and cash position increased by 51.9% to approximately RMB1,338.8 million for the six months ended June 30, 2024, compared with the six months ended June 30, 2023.- Dorzagliatin manufacturing capacity continues to expand, with the expectation to reach 3 million packs in 2024. New processes for larger capacity have been established with our partners and are under regulatory review for production permit.- Post marketing clinical studies proceeded at an accelerated rate, in which HMM0601 enrolled 1,368 patients and HMM0701 enrolled 102 patients. HMM0601 is designed to evaluate the long-term safety of dorzagliatin by collecting 1-year clinical safety data in 2,000 T2D patients and HMM0701 is a prospective real-world study to explore dorzagliatin’s clinical beneficial effects on the improvement of glucose homeostasis, cognitive function and diabetes remission. A good drug safety profile for dorzagliatin has been observed since its commercial launch in October 2022 – a time span of over 20 months and approximately 100,000 patient exposure.- Two Mendelian randomization studies conducted by our collaborating Hong Kong-based clinical investigators, and published in Cardiovascular Diabetology showed that glucokinase activation can lead to long term benefits in reduction of risks in cardiovascular diseases and dyslipidaemia. New clinical indications shall be further explored with our commercialization partner.HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company’s business progress for the first half of the year and business outlook.Dr. Li Chen, the founder and CEO of Hua Medicine, said, “The first half of 2024 marks a milestone for the commercialization efforts of Hua Medicine. Dorzagliatin's successful inclusion in China’s National Reimbursement Drug List has significantly improved patient accessibility and affordability. Against the backdrop of comprehensive support from the national and local governments for the development of the biopharmaceutical industry, and with the joint efforts of the Company, commercial partners, and production partners, the production capacity of dorzagliatin is rapidly increasing, accelerating its entry into hospitals and pharmacies nationwide to benefit more patients. With the continued growth in the number of users, the safety of dorzagliatin has been well validated, and its economic and social benefits have also greatly increased, instilling confidence in the Company's future development. Through sales expansion and operational optimization, we hope to achieve profitability for the Company by 2025. Currently, Hua Medicine is also conducting basic and clinical research on dorzagliatin globally, aiming to continuously expand its indications and target populations, explore new disease areas, and promote human health and well-being.”Progress of Clinical Research and Company Operations- During the first reporting period under the NRDL, dorzagliatin experienced a fast entry into hospital and pharmacies, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. The number of hospitals prescribing dorzagliatin exceeded 2,100 in the first half of 2024.- Revenue of dorzagliatin reached RMB102.7 million in the first half of 2024 and is expected to continue to grow in the second half of 2024. As we build off our new foundation under the NRDL, we plan to leverage our well-established partnerships to enhance the dorzagliatin manufacturing process, which is expected to lead to efficiencies, expanded capacity and reduction of cost of goods.- We continued our post marketing clinical studies at approximately 80 hospitals to better understand the benefits dorzagliatin provides to patients with Type 2 diabetes and T2D complications, such as memory loss and diabetes kidney disease. Through our collaboration with our clinical research partners in Hong Kong, we have discovered that glucokinase (GK) activation may bring the benefits of reduction of risks in cardiovascular disease, and dyslipidemia. These results (applying the Mendelian Randomization (MR) methodology) certainly expand our understanding of the benefits of GK activation through dorzagliatin and for uncovering new indications of dorzagliatin in the future. Mendelian Randomization (MR) is a statistical method that uses genetic variants to investigate the causal effects of exposures (e.g., treatments) on outcomes (e.g., diseases). Its unique advantage lies in its reduced susceptibility to confounding and time-related biases compared with observational studies, which is achieved by leveraging the random allocation of genetic variants at conception. In evidence-based medicine, the credibility of evidence from MR is considered to be among the highest, second only to that of randomized controlled trials.- We have advanced our post-marketing real world evidence (RWE) studies HMM0601 and HMM0701 in T2D patients in China, and HMM0123 in Hong Kong, China. In these studies, we are collecting evidence in medical practices for optimization of glucose homeostasis either through dorzagliatin alone or in combination with standard care T2D medications such as metformin, DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1RA and insulin. These results create new evidence for dorzagliatin in the expansion of its indication in diabetes prevention and remission.- We are continuing our drug development pipeline with focus on the fixed dose combination (FDC) of new drug candidates. The new drug Dorzagliatin-Metformin FDC entered manufacturing process validation and our plan is to launch this new medicine for Type 2 diabetes in 2028. Additional new FDC drugs with dorzagliatin will be developed for T2D patients, tailored specifically to address T2D patients with associated complications such as obesity and diabetes kidney disease.- To further leverage the unique advantage of dorzagliatin in restoring GLP-1 secretion in patients with diabetes and obesity, Hua Medicine initiated its Phase I study in the United States with our 2nd generation GKA. The trial has been proceeding smoothly and has already completed dose escalation in three cohorts of T2D patients in the United States. The topline data is expected to be available in the fourth quarter of 2024, supporting future drug development.- At the American Diabetes Association (ADA) Annual Meeting 2024, Hua Medicine reported new scientific data supporting the combination of dorzagliatin with a SGLT-2 inhibitor which led to improvement in glycaemic control. Combination of dorzagliatin with chronic kidney disease (CKD) medicine, such as SGLT-2 inhibitor, empagliflozin, in mid to late stage diabetes kidney disease patients, offers new opportunity to expand dorzagliatin’s indication.- We are exploring more drug repurposing opportunities for dorzagliatin using MR framework, such as renal diseases, neuropathy related diseases, eye related diseases, cognitive disorders, and cancers. Animal studies shall be further performed to validate the promising findings.- We are continuing to optimize our protein allosteric modulation technology (PAMT) and expansion from positive allosteric modulator (PAM), such as GK positive allosteric modulator dorzagliatin, to negative allosteric modulator (NAM) in kinase and G-protein-coupled receptors (GPCR) proteins. The GK NAM program advanced to the pre-clinical candidate (PCC) selection stage and final optimization of the PCC to clinical candidate for congenital hyperinsulinism (CHI), and potentially for dyslipidaemia. We continue to advance mGLUR5 NAM program for its clinical potential in Parkinson’s disease (PDLID), Fragile X syndrome (FXS), and drug addiction.Financial highlightsAs of June 30, 2024,- Bank balances and cash position was approximately RMB1,338.8 million.- Total revenue generated by the Company was approximately RMB102.7 million, reflecting sales of approximately 846,000 packs of HuaTangNing .- Total other income was approximately RMB55.1 million, of which approximately RMB47.8 million was attributable to the amortization of Bayer milestone income.- Total expenditures was approximately RMB245.9 million, of which approximately RMB119.8 million was attributable to research and development expenses.Forward-looking StatementThis article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product. The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect as a result of various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.comDisclaimerFor the accuracy and completeness of the context, references to information related to products launched in China, especially label or requirements, should follow the relevant documents approved by the Chinese regulatory authorities.The above information should not be interpreted as a recommendation or promotion of any drug or treatment regimen, nor should it substitute for the medical advice of any healthcare professional. Please consult a healthcare professional for any matters related to medical treatment. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 2024年8月28日，复星国际（HKEX: 0656）公布2024年中期业绩。报告期内，总收入保持增长，达人民币978.4亿元；产业运营利润保持增长，达人民币34.7亿元，归母净利润为人民币7.2亿元。复星国际董事长郭广昌在29日上午的业绩发布会上表示，「上半年，尽管宏观环境充满挑战，我们坚定执行聚焦主业战略，围绕形成优势的产业赛道，打造行业数一数二的好公司、好产品，总体来看卓有成效。我们将持续聚焦创新、聚焦全球化，同时注重轻资产运营，以具备竞争优势的核心能力驱动长远发展。」今年以来，国内经济恢复不稳固，国际市场持续波动，让包括复星在内的中国企业面临诸多挑战。复星持续推进战略聚焦，以核心能力驱动企业发展，实现核心产业提质增效，资产底盘保持稳健。分析人士认为，从复星中期业绩报告释放的信息来看，复星聚焦家庭消费核心产业，先人一步推进创新和全球化，这一战略持续为复星夯实业务底盘，带来可预期的稳定赢利；同时，这两年复星积极推进轻资产运营，优化资产组合，持续降低杆杆，现金储备充裕，财务安全垫日渐厚实，有望推动市场对复星的价值进行重估。全球化和创新「先人一步」，打造「数一数二」的企业和产品 今年上半年，复星四大核心子公司——复星医药、豫园股份、复星葡萄牙保险、复星旅文，总收入达人民币721.7亿元，占集团总收入的比重达到74%。复星聚焦主业的效果进一步显现，其在医药、旅游、消费、保险等核心产业赛道的优势持续提升。在上述核心赛道，通过多年努力，复星已打造出多个在行业排名前列的「数一数二」的企业和产品。例如，复星医药位列中国医药工业百强第二名，今年上半年也连续第三年入选全球药企管线规模前二十强；复宏汉霖是首个在港股赢利的中国创新生物制药公司，旗下多款自主开发的单抗生物类似药，引领中国生物医药行业快速发展，首款重磅产品汉利康是首个获批上市的国产生物类似药；复星葡萄牙保险在葡萄牙保险市场市占率保持第一，在全球葡语区保险市场居前列；智造板块的翌耀科技是全球领先的自动化和数字化企业。此外在快乐业务板块，复星旅文旗下Club Med是精致「一价全包」度假的全球领导者；三亚亚特兰蒂斯是国内领先的高端综合度假旅游目的地，推动海南旅游进入3.0时代；豫园旗下老庙黄金，是中华老字号，更是享誉全国的珠宝品牌。这些在各自行业「数一数二」的企业和产品，帮助复星持续巩固在相关产业的领导地位。对复星而言，稳健赢利的增长来自两个方面，一是创新，一是全球化。在当前国内经济「内卷」的大环境下，「出海」成为企业界的「必答题」。但复星早在2007年便启动全球化征程，在海外摸爬滚打17年，今天已成为植根中国的标杆性的全球化企业之一、在全球超过35个国家和地区拥有深度产业布局。17年出海征程里，复星捕获了很多成功的项目，也遇过很多挑战，最重要的意义在于锻造了国内企业稀缺的全球化能力，并在全球打通不同市场、不同业态和资源，实现了全球布局、全球运营和全球发展，全球化深度运营能力持续提升。有一组数据非常能阐释情况，2024年上半年，集团海外收入达人民币458.7亿元，同比增长4%，占总收入的比重上升至47%，近半收入来自海外，这在中国企业中并不多见。更重要的是，复星在全球化过程中积极推进旗下企业生态赋能与协同，旗下海内外成员企业在全球化研发、业务拓展、运营及投融资等方面取得多项进展。上半年，复星旗下企业的生物药出海再获突破。复星旗下的复宏汉霖，自主开发的汉曲优获得美国食品药品监督管理局批准上市，成为在中国、欧盟、美国获批的「中国籍」单抗生物类似药；中国首个生物类似药汉利康获得秘鲁药监局批准上市，成为继汉曲优和汉斯状后，复宏汉霖第三款海外获批上市的自研药品。再如复星旅文Club Med地中海俱乐部在全球运营67家度假村，2024年上半年营业额再创新高，达人民币88.9亿元，同比增长10.3%。其中，欧非中东及美洲区持续增长，亚太区复苏显著。2024年5月，Club Med 在阿曼签约中东首个度假村。复星葡萄牙保险，从葡萄牙出发积极拓展海外市场，今年上半年取得葡萄牙境内和国际业务双增长，海外业绩占比进一步提升，国际业务录得总保费欧元8.85亿元，占比超过30%；国际业务净利润约欧元0.51亿元，占比超过40%。复星旗下全球领先的自动化和数字化企业翌耀科技，也在静悄悄推进海外拓展，2024年上半年海外新增订单达到人民币39.9亿元，其中美国市场订单大幅增加，新增订单达到人民币7.5亿元，同比增长超过一倍。创新同样是复星长期积累并始终坚持的核心能力。报告期内，复星持续深化科技与创新能力，创新投入达人民币35亿元；全球视野下的整合式创新模式更加成熟，一批突破性成果正持续为复星带来稳健赢利，成为复星的增长动力。从创新药研发方面来看，复星医药共有4个产品共9项适应症获批上市，4个产品共9项适应症进入上市前审批/关键临床阶段，9项产品（按适应症计算）获批开展临床试验。复宏汉霖自主研发并生产的创新生物药不断取得突破性进展，全球首个一线治疗小细胞肺癌的抗PD-1单抗汉斯状已获批4项适应症，累计惠及患者超7.5万，对外授权覆盖美国、欧洲、东南亚、中东和北非等70多个国家和地区。此外，新一代口服血小板生成素受体激动剂（TPO-RA）苏可欣新适应症也获得国家药监局批准。尖端医疗器械及创新疗法的布局也取得新进展。2024年6月，直观复星总部产业基地在上海启用，是直观医疗在亚太地区最大的研发、生产和培训一体化基地，达芬奇手术机器人国产化显著提速。直观复星Ion支气管导航操作控制系统也于2024年3月通过国家药监局批准，并于7月上市。 「轻资产运营」打法成型，价值重估可期得益于业务面的坚实支撑，复星财务面也持续改善。报告期内，复星持续优化资产组合，降低杆杆，财务状况保持稳健。截至报告期末，集团调整后总债务占总资本比率为50.2%，维持了2020年以来的下降趋势；调整后NAV为每股港币17.4元，显示当前复星国际股价被严重低估。复星也在积极夯实财务安全垫，保持充裕的现金储备。这次报告期内，复星国际现金、银行结余及定期存款达到人民币1095.5亿元，较2023年底增加人民币约171亿元。上市17年来，累计分红港币256亿元，分红率逐渐提升，近五年分红率在20%及以上。就在 2024年6月，国际评级机构标普也充分肯定复星财务战略成效，确认评级展望为「稳定」。在通过持续的创新和全球化实现稳定赢利的同时，复星面对新的市场环境，也继续推进「瘦身健体」，陆续退出一些非核心产业，同时积极推进「轻资产运营」，打法也逐渐成型。2024年5月，复星出售德国私人银行HAL 99.74%股份，引起市场关注，交易完成后，复星将不再持有HAL股份，但全额保留HAFS基金服务业务，以轻资产运营模式，管理约千亿欧元资产。在文旅赛道，复星的轻资产运营模式成效显著，Club Med、三亚亚特兰蒂斯、太仓阿尔卑斯等IP成为国内旅游行业标杆。报告期内，Club Med采用租赁及管理模式的度假村占比为85%，自持度假村占比降至15%。2024年4月，复星旅文在丽江地中海国际度假区打造的全新IP——阿美泽雪山营地对外开放后，迅速火爆「出圈」，带动度假区内Club Med丽江度假村与丽江地中海棠岸度假酒店入住率显著提升。2024年6月，复星旅文还携手太仓市政府共同打造一站式冰雪主题旅游度假目的地太仓阿尔卑斯国际度假区二期。该项目总投资超人民币50亿元，由太仓市政府平台出资打造，由复星旅文运营管理。此前复星旅文对阿尔卑斯雪世界的成功运营，为二期项目提供了信心和动力，该项目有望打造多项「世界雪场之最」。与此同时，复星携手合作伙伴打造了一批产业基金，深度布局优势产业。2024年3月，复星医药依托在生物医药领域的领先优势，联手深圳市引导基金等其他七方投资人，共同出资设立人民币50亿元生物医药产业基金，募集资金全部投资于生物医药、细胞和基因等领域。复星医药旗下复健资本通过深圳市公开遴选中标，独家管理该基金。4月，深圳市政府与复星签署战略合作框架协议，双方集聚优质创新资源，进一步加强在生物医药、文体旅游、时尚消费等领域的合作。也是在2024年4月，复星创富联合武创投、武汉基金，设立人民币30亿元产业基金，首期规模人民币11亿元。这是湖北省设立人民币200亿元政府引导基金以来，第一只出资的市场化基金，主要聚焦新一代信息技术、双碳、智能制造、大消费四大赛道。面对当前的市场环境，可以预计，未来复星仍将积极推进轻资产运营，持续扩大「朋友圈」，加强与各方深度合作，通过优势互补，实现共赢。多位市场分析人士认为，复星通过创新和全球化的核心战略，推动业务实现持续稳定盈利，通过退出非核心产业、轻资产运营，持续降债等措施，保持财务面的稳健，有望推动市场对复星的价值重估。郭广昌认为，未来投资者会更加看重核心产业增长和现金流的稳健，「一次性的资产出售都是短期的，核心业务的成长，才是企业稳健赢利的核心因素」，复星希望打造一个聚焦核心产业的家庭消费产业集团，产业的发展和赢利更可预期。无论是集团层面还是每一块业务，都要给客户、投资人提供风险可控、能稳健成长的企业价值。 Copyright 2024 亚太商讯 via SeaPRwire.com.

- 全球首创新药双功能葡萄糖激酶激活剂（GKA）多格列艾汀（商品名：华堂宁®）于2023年底成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录》（“国家医保药品目录”）。华领医药与商业化合作伙伴拜耳以及80家一级经销商共同推动多格列艾汀的商业化，开始进入中国31个省级医药市场。- 2024年1月1日新版“国家医保药品目录”正式执行，2024年上半年，多格列艾汀的销售量显著增加。截至2024年6月30日，共销售84.6万盒，实现销售收入人民币1.027亿元，相比2023年6月30日，同比增长46%。- 得益于政府支持创新药品的市场准入政策，多格列艾汀加速进入上海、北京和天津等地医院。截至2024年6月30日，已有2100多家医院和2900多家药店开始了多格列艾汀的处方销售。多格列艾汀在医院、药店和网络药店销售的比例分别为72%、20%和8%。- 2024年上半年，公司毛利约为4780万元，毛利率为46.5%。截至2024年6月30日，公司银行结余及现金约13.388亿元，相比2023年6月30日，同比增长51.9%。- 多格列艾汀的生产能力继续扩大，预计2024年产能将达到300万盒以上，公司已经与合作伙伴建立了更大产能的新工艺，正在接受生产许可部门的监管审查。- 上市后临床研究加速进行，其中HMM0601研究已入组1368例患者，该研究旨在通过收集2000例2型糖尿病患者1年的临床安全性数据来评估多格列艾汀的长期安全性。HMM0701研究已入组102例患者，该研究是一项前瞻性真实世界研究，旨在探索多格列艾汀在改善血糖稳态、认知功能和糖尿病缓解方面的临床获益。自2022年10月上市销售以来，过去20个月约有10万名患者使用多格列艾汀，药物安全性良好。- 公司与中国香港临床研究人员合作开展了两项孟德尔随机化研究，结果显示，激活葡萄糖激酶（GK）在降低心血管疾病风险和血脂异常风险方面具有长期获益性，研究结果已经发表在《心血管糖尿病学》杂志上。公司将携手商业化合作伙伴进一步探索多格列艾汀更加广泛的临床适应症。香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 华领医药（“公司”，香港联交所股份代号：2552）宣布公司及其附属公司截至2024年6月30日止，6个月（“报告期”）未经审核的综合业绩，以及公司上半年业务进展和未来业务展望。华领医药创始人、首席执行官陈力博士表示：“2024年上半年是华领医药商业化进程的又一个里程碑。多格列艾汀成功纳入国家医保药品目录，大大提升了患者用药的可及性和可负担性。在国家和各级政府全链条支持生物医药产业发展的背景下，在公司与商业化伙伴和生产伙伴的共同努力下，多格列艾汀正迅速提升产能，加速进入全国各地的医院和药房，以惠及更多患者。随着用药人数的持续增长，多格列艾汀的安全性得到了良好的验证，其经济效益和社会效益也大幅提升，为公司未来发展注入了信心。通过销售扩张和优化运营，我们希望能够在2025年实现公司盈利。目前，华领医药还正在全球范围内开展多格列艾汀的基础研究和临床研究，希望不断拓展多格列艾汀的适应症和适用人群，探索更加广泛的疾病应用领域，造福不同的患者人群。”临床研究和公司运营进展摘要- 进入国家医保药品目录后，多格列艾汀速进入医院和药店，尤其在上海、北京、天津等城市，政府推出了支持创新药进入市场的政策。截至2024年上半年，多格列艾汀已经进入全国2100多家医院。- 上半年，多格列艾汀实现销售收入人民币1.027亿元，预计在2024年下半年将继续增长。基于进入医保建立的新基础，公司正不断与合作伙伴密切协作，优化多格列艾汀的生产流程，提高生产效率，从而扩大产能并降低生产成本。- 公司继续在约80家医院开展上市后真实世界研究，增进了解多格列艾汀对于2型糖尿病及其并发症（如记忆力减退、糖尿病肾病）患者的获益。除此之外，通过与中国香港的临床研究伙伴的合作，我们使用孟德尔随机化(MR)研究发现激活GK可以降低心血管疾病和血脂异常风险，有助于公司通过多格列艾汀进一步了解GK激活的更多获益，并探索多格列艾汀新的适应症。孟德尔随机化是一种统计方法，利用遗传变异体来研究暴露（如治疗）对结果（如疾病）的因果效应。MR的独特优势在于它比传统的观察性研究更不容易受到混杂因素和时间相关偏倚的影响，因此在循证医学中，当随机对照试验不可实施时，MR被视为最高循证医学证据。- 公司正在积极推进针对2型糖尿病患者的上市后真实世界研究，包括在中国内地的HMM0601研究和HMM0701研究，以及在中国香港的HMM0123研究。在这些研究中，公司正不断积累多格列艾汀单独用药，以及多格列艾汀与二甲双胍、DPP-4抑制剂、SGLT-2抑制剂、GLP-1RA和胰岛素等联合用药的临床数据，以优化血糖稳态治疗的临床证据，并且为多格列艾汀拓展在糖尿病预防和缓解等方面的适应症提供新的证据。- 公司正在持续丰富药物开发管线，尤其是固定复方制剂的开发。多格列艾汀-二甲双胍固定复方剂量已经进入生产工艺验证阶段，公司预计将于2028年推出2型糖尿病治疗的新药。未来，公司将开发更多的多格列艾汀固定复方制剂新药用于糖尿病及其并发症，如肥胖、糖尿病肾病等的个性化治疗。- 为了进一步发挥多格列艾汀在修复伴有肥胖的糖尿病患者的GLP-1分泌方面的独特优势，公司在美国启动了第二代GKA的1期临床研究。目前，试验进展顺利，在3组2型糖尿病患者中完成了剂量递增。公司预计在2024年第四季度发布顶线数据，以支持未来的药物开发。- 在2024年美国糖尿病协会（ADA）科学年会上，公司报告了多项基础研究和临床研究进展。一项研究显示，多格列艾汀联合SGLT-2抑制剂可以改善血糖控制，联用效果优于两者单独用药，并且提示多格列艾汀有望在新的适应症中发挥作用，用于与SGLT-2抑制剂恩格列净等慢性肾病治疗药物联合用药，治疗中晚期糖尿病肾病患者。- 公司正在使用孟德尔随机化研究的框架探索多格列艾汀更多的药物使用机会，如肾病、神经病变相关疾病、眼部相关疾病、认知障碍和癌症等。公司将进一步利用动物研究验证更多可能的机遇。- 公司将持续优化蛋白变构调节技术，并积极扩展应用领域，推进负向变构调节剂在GK和GPCR蛋白上的应用。目前葡萄糖激负向变构调节剂已经进入临床前药物候选阶段，作为先天性高胰岛素血症和潜在的血脂异常症的临床候选药物。公司将继续推进mGLUR5 NAM项目在帕金森病（PDLID）、脆性X染色体综合征(FXS)和药物成瘾中的临床潜力。财务摘要截至2024年6月30日止，- 公司银行结余及现金约13.388亿元- 销售收入约为人民币1.027亿元，共销售84.6万盒华堂宁®- 其他收入约为5510万元，其中拜耳里程碑收益摊销约4780万元- 开支总额约2.459亿元，其中研发开支约1.198亿元前瞻性声明本文包含有关华领医药以及产品未来预期、计划和前景的陈述。该等前瞻性陈述仅与本文作出该陈述当日的事件或资料有关，可能因未来发展而出现变动。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请仔细阅读本文并理解，由于各种风险、不确定性或其他法定要求我们的实际未来业绩或表现可能与预期有重大差异。关于华领华领医药是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁®（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁®已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于不同程度的肾功能损伤（包括未进行透析的终末期肾损）的2型糖尿病患者的口服降糖药物。华领医药将与领军企业拜耳共同推动华堂宁®在中国的商业化推广，以造福糖尿病患者及其家庭。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com新闻免责声明本材料，如为上下文论述的准确性和完整性，提及在中国上市的产品相关信息的，特别是标识或要求，应遵循中国监管机构批准的相关文件。另外，相关信息不应被解读为对任何药物或者诊疗方案的推荐或者宣传，亦不应替代任何医疗卫生专业人士的医疗建议，涉及医疗的相关事宜务必咨询医疗卫生专业人士。 Copyright 2024 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - Baguio Green Group Limited (‘‘Baguio’’ or the ‘‘Group’’, Stock Code: 01397.HK) is pleased to announce its unaudited interim results for the six months ended 30 June 2024 (the Period”).During the Period, the Group’s revenue amounted to approximately HK$1,291.1 million, representing an increase of approximately 16.6% as compared to the same period last year, mainly due to the continued increase in revenue in the cleaning segment together with the waste management and recycling segment. Profit for the Period amounted to approximately HK$25.8 million, representing an increase of approximately 18.5% as compared to the same period last year. The overall gross profit increased by approximately 12.4% to approximately HK$97.1 million.Business Overview and ProspectsIn the first half of 2024, new contracts awarded to the Group amounted to a total of HK$1.48 billion. As a result, the Group’s contracts on hand reached approximately HK$4.60 billion (as of 30 June 2024), representing an increase of approximately 3.8% from approximately HK$4.43 billion as of 31 December 2023, providing strong revenue growth in the second half of 2024 and subsequent years.The Group’s core business, cleaning services, recorded growth during the Period. Revenue from cleaning services increased by 20.1% to approximately HK$1,034.9 million, accounting for approximately 80.2% of the Group’s total revenue. Gross profit of the cleaning business increased by 7.6% to approximately HK$66.4 million, mainly due to the Group’s new cleaning service contracts with various HKSAR Government (the “Government”) departments and different institutions.The Group’s Government-related street cleaning services cover a total of seven districts, serving a population of approximately 2.8 million, marking Baguio’s leading position in the Hong Kong cleaning services market. The Group’s Government venue cleaning services for the Food and Environmental Hygiene Department cover seven districts in Hong Kong. In addition, the Group also provided Government market related cleaning services and leisure venues cleaning services, covering several districts in Hong Kong, as well as other cleaning sites such as hospitals, Government clinics, Hong Kong International Airport, schools, housing estates and private institutions, demonstrating that the Group’s professional services are widely recognised.Waste management and recycling business recorded growth in revenue during the Period which increased by approximately 7.4% to approximately HK$147.3 million, accounting for approximately 11.4% of the Group’s total revenue. Gross profit of the waste management and recycling business increased by approximately 60.7% to approximately HK$19.2 million, mainly due to the “Plastic Recycling Pilot Scheme” entered the harvest period and the related contracts with the Government increased the recycling spots and revenue. During the Period, the Group provided Government-related waste collection services to five districts, serving a population of approximately 1.6 million, and provided collection services for thousands of recycling spots (including plastic, glass bottles, metals, waste paper and food waste) across Hong Kong, and collection services for recycling bins in public places and schools. During the Period, the Group provided Baguio continued to provide plastic collection services for several districts under the Environment Protection Department (“EPD”) Plastic Recycling Pilot Scheme contract. Baguio also provides collection services for Recycling Stations of “GREEN@COMMUNITY”, introduced by the EPD and smart recycling machines, and other institutions in Hong Kong. In addition, the Group also provides the Government with glass bottles collection and management services and food waste collection services in several districts in Hong Kong.Regarding green technology business, the Group launched a smart recycling system through combination of a number of advanced smart digital technologies and Internet of Things technologies. Through a one-stop management and big data analytics platform, the Group can monitor the real-time situation of the recycling machines, and flexibly deploy transportation according to the amount of recyclables, reducing logistics costs and unnecessary carbon emissions. The Group currently provides smart recycling machines to the EPD and smart food waste recycling machines to private housing estates. At present, smart recycling machines and smart food waste recycling machines are now available in different places of Hong Kong, providing the public with a convenient recycling experience 24 hours a day, and helping to increase the overall recycling volume in Hong Kong. The Government is proactively offering financial aids for private housing estates to install food waste recycling machines through the Recycling Fund and the Environment and Conservation Fund. Under the expected market demand created by the strong advocacy of the Government, it is believed that the Group’s food waste recycling machines and related smart technology business will bring huge business opportunities. With the increasing market demand for smart recycling, the Group plans to seize the opportunity of smart city development, striving to expand the market share of smart recycling machines and smart food waste recycling machines.In addition, the Government is actively promoting the “Producer Responsibility Scheme on Plastic Beverage Containers and Beverage Cartons”, and plans to table the bill to the Legislative Council for scrutiny this year with a view to introducing it in 2025. Enshrining the principle of “Polluter Pays” and the vision of “Eco-responsibility”, the recycling rate of plastic beverage containers and beverage cartons is expected to have a significant increase. The scheme is expected to directly drive the growth of Baguio’s recycling business and create solid returns from our investment in recycling facilities which creates a strong entry barrier to the competition.In partnership with Jardine Engineering Corporation Limited, the Pilot Biochar Production Plant at the EcoPark in Tuen Mun was commenced trial operation during the Period. By converting yard waste into high-quality biochar with pyrolysis technology for various applications, the production plant effectively “turns waste into useful resources”.Hong Kong has made concerted effort to keep pace with international trends in the field of green and sustainable finance, accelerating its progress towards becoming an international green finance hub. To meet the needs of sustainable development, the Group has incorporated sustainability insights into its core businesses and operations and is committed to providing customers with one-stop and diversified green environmental services and sustainable procurement solutions. In the future, Baguio will invest more resources in personnel training and green procurement. Meanwhile, through the provision of waste audit services, the Group provides waste constituent data to help corporate customers understand the amount of generated waste that can be recycled and achieve sustainable development goals.As for the landscaping business, the Group provided landscaping services for the Kai Tak Sports Park, the Central and Western District Promenade and the Inclusive Park for Pets at Tsun Wen Road in Tuen Mun. In addition, the Group provides landscaping services for a wide range of clients, including large private residences, Government premises, schools, shopping malls, hotels, airports, Hong Kong Science Park, Hong Kong University of Science and Technology and Lingnan University, etc.For pest management business, the Group continued to provide pest management services in Wong Tai Sin and Tai Po districts during the Period. In addition, the Group provided termite control and monitoring services to 29 monuments under the Antiquities and Monuments Office and 24 temples under the Chinese Temples Committee respectively.The Government is developing the Northern Metropolis at full speed and a number of public housing estates are scheduled for completion in phases. In particular, intake of tenants at the public housing estates in northern Kwu Tung North and Fanling North New Development Area will commence progressively from 2026. The Northern Metropolis will provide about 500,000 new housing units after fully developed, which is believed to bring opportunities to the Group’s core businesses.Mr. Ng Wing Hong, Chairman of Baguio, commented, “The Government demonstrates a strong commitment to environmental agenda. Baguio’s core businesses are closely related to the livelihood of the general public and are not affected by the economic environment. Despite the presence of economic headwinds, the Group’s core business continues to demonstrate a growth trajectory.While the implementation of the Waste Charging was postponed during the Period, the Government has significantly increased its efforts to increase various types of recycling spots through recyclers. For example, the addition of night mobile food waste recycling spots to facilitate citizens’ recycling, with improvement in terms of quality and quantity, which directly brings growth impetus to the Group’s recycling business. Therefore, the postponement of Waste Charging has no adverse impact on the Group’s recycling business, and on the contrary, results in an increase in business. In the long run, waste reduction and recycling will help achieve the Government’s goal of “Zero Landfill”, and benefit the development of the Group’s recycling and green technology businesses.”Looking forward, the Group will continue to increase the market share of its core businesses and proactively engage in expansion in Hong Kong and beyond. Meanwhile, in line with the development of the Group, it will actively explore potential mergers and acquisitions, joint ventures or new business projects to accelerate future business growth and deliver substantial and long-term returns to shareholders.For details of the Group's 2024 interim results announcement, please visit the following website:http://www.baguio.com.hk/en-US/Investor%20Relations/Announcements%20and%20Notices- End -About Baguio Green GroupEstablished in 1980, Baguio Green Group (Stock code: 01397.HK) is one of Hong Kong’s largest integrated environmental services groups. It provides a full spectrum of professional services including professional cleaning, waste collection & recycling, waste management, green technology, organic fertilizer and animal feed production, horticulture & landscaping, and pest control. It serves a wide range of customers in various sectors including Government departments, statutory organizations and multinational corporations. Fully committed to ESG, the Group works relentlessly to advance sustainable development and create a cleaner, greener, healthier city. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. The meningococcal conjugate vaccines demonstrated robust growth, particularly the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), known as MCV4 or Menhycia®. As the first quadrivalent meningococcal conjugate vaccine product in Asia, it not only fills the market gap, but also provides a better choice for the prevention of meningococcal disease in Chinese infants and young children. In the first half of 2024, CanSinoBIO's two meningococcal vaccines generated approximately 263 million yuan in revenue, marking a significant increase of around 18% compared to last year.In addition, CanSinoBIO is making strides in clinical trials for expanding the age group of MCV4, aiming to cover children aged four and above, as well as adults. This initiative seeks to broaden vaccination coverage to meet the needs of a wider population. Concurrently, the company is advancing the international market expansion of the MCV4, leveraging its successful overseas commercialization experience with its COVID-19 vaccine. CanSinoBIO is deepening collaborations with leading international research institutions, focusing on registration and commercialization in Southeast Asia, the Middle East, North Africa, and South America. It indicates that the company is accelerating the commercial layout in the global market.Moreover, the market expansion experiences and strategic partnerships will support to expand the reach of its PCV13i [13-valent pneumococcal conjugate vaccine (CRM197, TT Vector)] and DTcP (diphtheria, tetanus and acellular pertussis) components vaccine franchise in global markets. The company is also planning and preparing for WHO PQ certification, exploring the feasibility of international organizations. For global innovative products, CanSinoBIO will actively explore the possibility of accessing developed countries.In terms of commercialization strategy, CanSinoBIO has adopted an efficient and precise model, relying on its direct sales team and leveraging professional promoters to rapidly extend its marketing network to the county-level areas. The company adheres to a professional academic and customer-oriented approach, ensuring that products reach target groups through in-depth research and terminal services. This approach helps control sales expenses and achieves intensive operations. To date, CanSinoBIO has established a well-structured commercial operation center for both domestic and international markets. The MCV4 has been approved in 30 provinces in China, comprehensively opening up the domestic market. The successful commercialization of MCV4 has laid a solid foundation for the upcoming PCV13i, which is currently undergoing clinical and manufacturing site inspections as planned.CanSinoBIO has also made significant progress in cost reduction and efficiency improvement, with sales and administrative expenses decreasing by approximately 13% and 39% compared to the same period last year, respectively, reflecting ongoing improvements in operational efficiency.Overall, CanSinoBIO has integrated R&D, production, and commercialization, gradually transforming into a biopharmaceutical company. With the successful commercialization of MCV4 and the upcoming approval and launch of new products like PCV13i, CanSinoBIO's performance is expected to continue growing. The company’s management team is confident on the company's prospects and has demonstrated strong support through increasing shareholdings. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月29日 - (亚太商讯 via SeaPRwire.com) — 碧瑶绿色集团有限公司（“碧瑶”或“集团”；股份代号：01397.HK）欣然宣布截至2024年6月30日止六个月（“期内”）之未经审核之中期业绩。期内，集团收益约12.9亿港元，较去年增加约16.6%，主要由于集团清洁、废物处理及回收业务持续增长所致。期内溢利约为25.8百万港元，较去年同期增加约18.5%。整体毛利增加约12.4%至约97.1百万港元。业务回顾及展望2024年上半年，集团成功获得共14.8亿港元新合约，成功将集团的手头合约由2023年12月31日约44.3亿港元增加约3.8%至约46.0亿港元（截至2024年6月30日），为2024年下半年及日后年度，迎来可观的收益增长。清洁作为集团的核心业务，继续于期内录得增长，收益较去年同期增加20.1%至约10.3亿港元，占集团总收益约80.2%。清洁业务毛利增加7.6%，至约66.4百万港元，主要由于集团与香港特区政府（“政府”）各部门及不同机构的新清洁服务合约所致。集团为政府辖下的街道清洁服务版图，覆盖全香港共七区，服务人口约280万，标志碧瑶于香港清洁服务市场的领导地位。集团为食物环境卫生署管理政府场地清洁服务版图，覆盖全港七区。另外，集团亦为政府多区辖下的街市及康乐场地提供清洁服务，覆盖全港各大区，其他清洁场地亦遍及各大医院、政府诊所、香港国际机场、学校、屋苑及私人机构等众多不同场景，显示集团的专业服务广受认可。废物管理及回收方面，期内收益录得增长，同比增加约7.4%至约1.47亿港元，占集团总收益约11.4%。废物管理回收业务的毛利增加约60.7%，至约19.2百万港元，主要由于“塑胶回收先导计划”进入收成期，以及相关政府合约增加回收点及收入所致。集团期内为政府辖下的五区提供废物收集服务，服务人口约160万，亦为香港数千个回收点（包括塑胶、玻璃樽、金属、废纸及厨余），连同公共场所及学校的回收箱，提供收集服务。期内，集团继续为环境保护署（“环保署”）的“塑胶回收先导计划”服务合约，为香港多区提供塑胶收集服务。此外，集团亦为香港众多环保署辖下的“绿在区区”回收环保站、智能回收机及不同机构提供回收服务，负责香港多区的玻璃容器收集及处理，以及厨余收集服务。绿色科技业务方面，集团结合多项先进的智能数码科技和物联网技术，推出了智能回收系统。透过一站式管理及大数据分析平台，即时了解回收机的情况，并可根据回收量，灵活调配运输，减少物流成本和不必要的碳排放。集团现时为环保署提供智能回收机，以及为私人屋苑提供智能厨余回收机。目前智能回收机及智能厨余回收机已遍及香港不同角落，每日24小时为市民提供便捷的回收体验，并有助提升香港整体回收量。政府现正积极透过回收基金和环境及自然保育基金，向私人屋苑提供全面的财务支援，作安装厨余回收机之用。在政府大力宣传所创造的市场需求下，预计为集团厨余回收机以及相关智能科技业务，带来庞大商机。随着市场对智能回收的需求日渐上升，集团计划把握智慧城市发展的契机，致力扩大智能回收机及智能厨余回收机的市场份额。此外，政府积极推展“塑胶饮料容器及纸包饮品盒生产者责任计划”，计划今年将条例法案提交立法会审议，预计2025年推出。贯彻“污染者自付”的原则和“环保责任”的理念，相信有助大幅增加塑胶饮料容器及纸包饮品盒的回收率。受益于该计划，预计将直接拉动碧瑶回收量，为集团多年来于回收服务建设的投资及竞争壁垒，提供吸引回报。期内，集团与怡和机器有限公司合作位于香港屯门环保园的生物炭工厂已试营运，通过热解技术将园林废料转化为高质量生物炭以作各种应用，从而达到“转废为材”的目的。香港在绿色和可持续金融的领域紧贴国际趋势，加速朝着国际绿色金融中心的方向迈进。为配合可持续发展的需求，集团将可持续发展概念注入核心业务和营运范畴，致力为客户提供一站式及多元化绿色环境服务及可持续采购方案。未来，碧瑶将投放更多资源在人力培训及绿色采购。同时，集团透过提供废物审计服务，提供废物成份数据，协助企业客户了解产出废物的可回收量，实现可持续发展的目标。园艺方面，集团为启德体育园、中西区海滨长廊及屯门震寰路宠物共享公园提供园艺工程。集团园艺服务的客户广泛，涵盖大型私人住宅、政府处所、学校、商场、酒店、机场、香港科学园、香港科技大学及岭南大学等。虫害管理方面，集团期内继续为黄大仙区及大埔区提供虫害管理服务。此外，集团分别为古物古迹办事处辖下29个古迹及华人庙宇委员会辖下24间庙宇，提供白蚁防治及监测服务。政府正全速发展北部都会区，预计众多公营房屋陆续落成，其中古洞北以及粉岭北新发展区的公共屋邨，预计于2026年开始陆续入伙。北部都会区全面发展后，可提供约50万个新增房屋单位，相信为集团多个核心业务带来契机。碧瑶主席吴永康先生指：“政府高度重视环境议题，碧瑶主要业务与民生息息相关，属社会刚性需求，不受经济环境影响。即使在经济疲弱下，集团核心业务依然持续增长。尽管期内垃圾征费暂缓推行，但政府明显加大力度通过回收商，增加各类回收点，例如加设夜间厨余回收流动点，方便市民进行回收，不论质和量均有提升，直接拉动集团的回收业务，带来增长动力。所以，暂缓推行垃圾征费不单对集团回收业务没有构成负面影响，反而业务有所增长。长远而言，减废回收有助实现政府中「零废堆填」的目标，有利集团回收及绿色科技业务的发展。”展望未来，集团在致力提高各核心业务的市场份额的同时，积极于香港及以外地区扩张。同时因应集团的发展，适时寻找潜在的并购、合营、或新业务项目，加速未来业务增长，为股东缔造可观及长远回报。有关集团2024年度中期业绩公告详情，请浏览以下网址：http://www.baguio.com.hk/zh-HK/Investor%20Relations/Announcements%20and%20Notices ~ 完 ~碧瑶绿色集团简介：碧瑶绿色集团（股份代号：01397.HK）成立于 1980 年，为香港最大的综合环境服务集团之一，提供环卫保洁、资源回收、循环再造、废物管理、绿色科技、有机肥料及动物饲料生产、园艺绿化工程及害虫防治等。集团为不同领域的客户提供服务，包括政府部门、各大机构及跨国企业。集团努力不懈地提升环境、社会及管治(ESG)的表现，以推进集团的可持续发展，以实现将香港推动成为更清洁、更绿色、更健康城市的愿景。 Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月29日 - (亚太商讯 via SeaPRwire.com) — 康希诺生物今日披露了2024年上半年业绩报告，营收达到3.03亿元，其中流脑结合疫苗家族再度展现强劲增长动力，尤其是ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）（以下简称“MCV4”）曼海欣®作为亚洲首个脑膜炎球菌四价结合疫苗产品，不仅填补了市场空白，更为我国婴幼儿流脑疾病预防树立了新标杆。康希诺生物两款流脑疫苗于2024年上半年实现营业收入约2.623亿元，较去年同期显著增长约18%，同时亏损大幅收窄。MCV4不仅在婴幼儿市场备受瞩目，其扩龄临床试验也正稳步推进，旨在覆盖4周岁及以上儿童及成人群体，进一步扩展使用范围，满足更广泛人群的接种需求。同时，康希诺生物紧跟全球研发步伐，与多家国际顶尖研究机构深化合作，不断推动产品创新和技术突破，并加速产业化技术转移和商业化布局。依托新冠疫苗海外商业化的成功经验，MCV4疫苗的国际市场拓展已蓄势待发，以东南亚、中东、北非、南美为主要目标区域，推动注册和商业化工作。此外，国际市场拓展经验以及与相关方建立的战略合作关系，也将助力康希诺生物的13价肺炎结合疫苗、组分百白破疫苗组合等产品在海外市场的准入与商业化。同时，公司也在以WHO PQ认证为方向进行前期准备和筹划工作，探索国际组织采购产品的可行性；对于全球创新类产品，也会积极探讨于发达国家准入的可行性。在营销策略上，康希诺生物采用了高效精准的商业化模式，依托自主销售团队为核心，结合专业推广商的力量，迅速将营销网络下沉至县级地区，实现营销网络的全面覆盖。公司坚持以专业学术和客户需求为导向，通过深入调研和终端服务，确保产品精准触达目标群体，同时有效控制销售费用，实现集约化运营。截至目前，康希诺生物建立了体系完备的商业运营中心以开展国内外的营销工作，流脑结合疫苗完成了30个省份的准入工作，全面打开了国内市场。流脑结合疫苗的成功商业化也为即将获批的13价肺炎结合疫苗打下坚实基础，目前该产品正在按计划进行临床和生产现场检查。康希诺生物在降本增效方面也取得了显著成效，销售费用和管理费用较同期均有下降，分别降低了约13%和39%，显示出公司运营效率的不断提升。总体来看，康希诺生物正稳步向集研发、生产、商业化于一体的全能型Biopharma公司迈进。随着MCV4商业化的成功和13价肺炎结合疫苗等新产品的逐步获批上市，公司业绩有望持续增长。公司管理层对公司前景充满信心，并已通过增持公司股份的实际行动表达了坚定支持。 Copyright 2024 亚太商讯 via SeaPRwire.com.